HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION MARKET ANALYSIS

Market Challenges And Opportunities

Global Human Immunoglobulin (pH4) for Intravenous Injection Market – Drivers

Increasing incidence of disease outbreaks

The increasing incidence of disease outbreaks is escalating demand for advanced diagnostic measures, which is expected to boost the growth of the global human immunoglobulin (pH4) for intravenous injection market. For instance, the coronavirus disease (COVID-19) pandemic is the most recent outbreak which was first reported on January 1, 2020, in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO), around 1,991,562 cases of the coronavirus disease (COVID-19) were reported on April 16, 2020, across the globe.

Increasing approval of intravenous human immunoglobulin products

Approvals of intravenous human immunoglobulin products by regulatory authorities are expected to drive the growth of the human immunoglobulin (pH4) for the intravenous injection market during the forecast period. For instance, on May 4, 2023, The U.S. Food and Drug Administration (FDA)- the main drug and medical devices regulatory body in the U.S., approved Kamada Pharmaceuticals- a global biopharmaceutical company’s application to manufacture Cytogam (cytomegalovirus immune globulin intravenous injection) at its facility located in Israel to treat COVID-19.

Global Human Immunoglobulin Ph4 For Intravenous Injection Market: Restraints

The inefficiency of immunoglobulins to treat COVID- 19

The ineffectiveness of immunoglobin therapies can restrain the growth of the global human immunoglobulin ph4 for intravenous injection market. For instance, a study conducted on January  2022, by The National Institute of Allergy and Infectious Diseases (NIAID, part of the National Institutes of Health), concluded that adding anti-coronavirus hIVIG to a remdesivir regimen did not improve the health of a subset of adults hospitalized with COVID-19.

Test and trial in non-hospitalized patients and more investigations about the drug regimen can serve as an effective counterbalance to determine the actual efficacy of immunoglobins.

Lack of approval from WHO

The World Health Organization's recommendation against the use of ph4 Immunoglobins to treat coronavirus can restrain the growth of this market. For instance, according to the data published by WHO in December 2022, it was unknown whether IVIG products derived from pooled donor plasma contain high titers of SARS-CoV-2 neutralizing antibodies and the immunomodulatory effects of IVIG preparations, do not appear to benefit patients with COVID-19.

This can be overcome by using better substitutes and alternatives which have already been approved as an effective treatment against COVID-19.

Market Drivers:

• Increasing incidence of disease outbreaks
• Increasing approval of intravenous human immunoglobulin products